KR20240073008A - Cd137 및 종양 연관 항원에 결합하는 이중특이적 결합 단백질 - Google Patents
Cd137 및 종양 연관 항원에 결합하는 이중특이적 결합 단백질 Download PDFInfo
- Publication number
- KR20240073008A KR20240073008A KR1020247008121A KR20247008121A KR20240073008A KR 20240073008 A KR20240073008 A KR 20240073008A KR 1020247008121 A KR1020247008121 A KR 1020247008121A KR 20247008121 A KR20247008121 A KR 20247008121A KR 20240073008 A KR20240073008 A KR 20240073008A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- variable region
- chain variable
- binding protein
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240402P | 2021-09-03 | 2021-09-03 | |
| US63/240,402 | 2021-09-03 | ||
| US202263327700P | 2022-04-05 | 2022-04-05 | |
| US63/327,700 | 2022-04-05 | ||
| PCT/US2022/075846 WO2023034922A2 (en) | 2021-09-03 | 2022-09-01 | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240073008A true KR20240073008A (ko) | 2024-05-24 |
Family
ID=85413134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247008121A Pending KR20240073008A (ko) | 2021-09-03 | 2022-09-01 | Cd137 및 종양 연관 항원에 결합하는 이중특이적 결합 단백질 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240383978A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4395823A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532485A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240073008A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022337286A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230426A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023034922A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024008500A (es) * | 2022-01-09 | 2024-08-26 | I Mab Biopharma Co Ltd | Construcciones multiespecíficas y usos de estas. |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2564432A1 (en) * | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid .beta. peptide antibody and fragment of said antibody |
| JP2011524179A (ja) * | 2008-06-16 | 2011-09-01 | パトリス リミテッド | Lm−1抗体、機能性フラグメント、lm−1標的抗原、ならびにそれらを作製および使用するための方法 |
| CN106459165B (zh) * | 2014-04-01 | 2021-04-20 | 拜恩科技细胞&基因治疗有限公司 | 密封蛋白-6特异性免疫受体和t细胞表位 |
| EP3554544A4 (en) * | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| CN112020516B (zh) * | 2018-03-13 | 2025-01-03 | 塔斯克疗法有限公司 | 用于肿瘤特异性细胞清除的抗-cd25 |
| WO2020191344A1 (en) * | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
| US11261259B2 (en) * | 2019-08-12 | 2022-03-01 | I-Mab Biopharma Us Limited | Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof |
| JP2022545835A (ja) * | 2019-08-28 | 2022-10-31 | ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー | 甲状腺眼症の治療方法 |
| CA3164996A1 (en) * | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| PH12022552323A1 (en) * | 2020-03-31 | 2023-12-04 | Chugai Pharmaceutical Co Ltd | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| EP4301784A4 (en) * | 2021-03-02 | 2025-01-01 | NovaRock Biotherapeutics, Ltd. | Antibodies against claudin-6 and uses thereof |
-
2022
- 2022-09-01 CA CA3230426A patent/CA3230426A1/en active Pending
- 2022-09-01 WO PCT/US2022/075846 patent/WO2023034922A2/en not_active Ceased
- 2022-09-01 KR KR1020247008121A patent/KR20240073008A/ko active Pending
- 2022-09-01 US US18/688,630 patent/US20240383978A1/en active Pending
- 2022-09-01 AU AU2022337286A patent/AU2022337286A1/en active Pending
- 2022-09-01 EP EP22865806.8A patent/EP4395823A4/en active Pending
- 2022-09-01 JP JP2024513933A patent/JP2024532485A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240383978A1 (en) | 2024-11-21 |
| AU2022337286A1 (en) | 2024-02-29 |
| JP2024532485A (ja) | 2024-09-05 |
| WO2023034922A3 (en) | 2023-05-25 |
| EP4395823A4 (en) | 2025-07-16 |
| WO2023034922A2 (en) | 2023-03-09 |
| EP4395823A2 (en) | 2024-07-10 |
| CA3230426A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240383978A1 (en) | Bispecific binding proteins that bind cd137 and a tumor associated antigen | |
| AU2019264965B2 (en) | Antibodies specific to human Nectin4 | |
| US20230272063A1 (en) | Anti-claudin 18 antibodies and methods of use thereof | |
| EP3277305B1 (en) | Antigen binding molecules comprising a trimeric tnf family ligand | |
| CN108064237B (zh) | 包含tnf家族配体三聚体的抗原结合分子 | |
| KR20190095941A (ko) | 신규 tnfr 효능제 및 이의 용도 | |
| US20240067740A1 (en) | Antibodies to tnfr2 and uses thereof | |
| US20250277026A1 (en) | Antibodies against claudin-6 and uses thereof | |
| WO2020249071A1 (en) | Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof | |
| US20250002599A1 (en) | Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf-beta and uses thereof | |
| HK40112412A (en) | Bispecific binding proteins that bind cd137 and a tumor associated antigen | |
| CN118234511A (zh) | 与cd137和肿瘤相关抗原结合的双特异性结合蛋白 | |
| HK40112413A (en) | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGFβ AND USES THEREOF | |
| CN117425675A (zh) | Tnfr2抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |